Bicyclic amino derivatives and PGD2, antagonist containing them

Abstract

A compound of the formula (I): wherein: for example, a compound below: wherein: R 1 is CH 3 , H or Na; and X1—X2—X3 is: or its salt or a hydrate thereof is useful as PGD 2 antagonist and can be used as a drug for treating diseases in which mast cell dysfunction is involved, for example, systemic mastocytosis and disorder of systemic mast cell activation, and also tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, injury due to ischemic reperfusion, and as an anti-inflammatory agent. It is particularly useful in the treatment of nasal occlusion.

What is claimed is:  
     
       1. A compound of the formula (Ib):                    
       wherein                    
       A is alkylene which optionally is intercalated by a hetero atom or phenylene, contains an oxo group, and/or has an unsaturated bond;  
       B is hydrogen, alkyl, aralkyl or acyl;  
       R is COOR 1 , CH 2 OR 2  or CON(R 3 )R 4 ;  
       R 1  is hydrogen or alkyl;  
       R 2  is hydrogen or alkyl;  
       R 3  and R 4  each are independently hydrogen, alkyl, hydroxy or alkylsulfonyl  
       X 1  is a single bond, phenylene, naphthylene, thiophenediyl, indolediyl, or oxazolediyl;  
       X 2  is a single bond, —N═N—, —N═CH—, —CH═N—, —CH═N—N—, —CH═N—O—, —C═NNHCSNH—, —C═NNHCONH—, —CH═CH—, —CH(OH)—, —C(Cl)═C(Cl)—, —(CH 2 )n—, ethynylene, —N(R 5 )—, —N(R 51 )CO—, —N(R 52 )SO 2 —, —N(R 53 )CON(R 54 )—, —CON (R 55 )——SO 2 N(R 56 )—, —O—, —S—, —SO—, —SO 2 —, —CO—, oxadiazolediyl, thiadiazolediyl or tetrazolediyl;  
       X 3  is alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclic group, cycloalkyl, cycloalkenyl, thiazolinylidenemethyl, thiazolidinylidenemethyl, —CH═NR 6  or —N═C(R 7 )R 8 ,  
       R 5 , R 51 , R 52 , R 53 , R 54 , R 55  and R 56  each are hydrogen or alkyl;  
       R 6  is hydrogen, alkyl, hydroxy, alkyoxy, carbamoyloxy, thiocarbamoyloxy, ureido or thioureido;  
       R 7  and R 8  each are independently alkyl, alkoxy or aryl; and  
       n is 1 or 2;  
       wherein a cyclic substituent may have one to three substituents selected from the group consisting of nitro, alkoxy, sulfamoyl, substituted- or unsubstituted-amino, acyl, acyloxy, hydroxy, halogen, alkyl, alkynyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, aryloxycarbonyl, mesyloxy, cyano, alkenyloxy, hydroxyalkyl, trifluoromethyl, alkylthio, —N═PPh 3 , oxo, thioxo, hydroxyimino, alkoxyimino, phenyl and alkylenedioxy, or its salt or hydrate thereof, provided that those wherein X, and X 2  are a single bond, and X 3  is unsubstituted phenyl, and wherein X 1  is a single bond, X 2  is —O—, and X 3  is benzyl or tert-butyl are excluded.  
     
     
       2. The compound of  claim 1 , its salt or hydrate thereof, wherein:                    
     
     
       3. The compound of  claim 2 , its salt or hydrate thereof, wherein R is COOR 1 . 
     
     
       4. The compound of  claim 2 , its salt or hydrate thereof, wherein X 1  is phenylene or thiophenediyl, X 2  is a single bond, —N═N—, —CH═CH—, ethynylene, —O—, —S—, —CO—, —CON(R 55 )—, —N(R 51 )CO— and X 3  is phenyl or thienyl. 
     
     
       5. The compound of  claim 1 , its salt or hydrate thereof, wherein:                    
     
     
       6. The compound of  claim 5 , its salt or hydrate thereof, wherein B is hydrogen, both X 1  and X 2  are a single bond, X 3  is thienyl, thiazolyl, thiadiazolyl, isothiazolyl, pyrrolyl, pyridyl, benzofuryl, benzimidazolyl, benzothienyl, dibenzofuryl, dibenzothienyl, quinolyl or indolyl. 
     
     
       7. The compound of  claim 5 , its salt or hydrate thereof, wherein X 1  is phenylene, thiophenediyl, indolediyl or oxazolediyl, X 2  is a single bond, —N═N—, —CH═CH—, ethynylene, —S—or —O—, and X 3  is aryl or a heterocyclic group. 
     
     
       8. A composition comprising a compound according to  claim 1  and a pharmaceutically acceptable carrier thereof. 
     
     
       9. A method for treating a PGD 2 -mediated disease comprising administering to a subject in need thereof, a PGD 2  antagonist according to  claim 1 . 
     
     
       10. A compound A method according to  claim 9  wherein said PGD 2 -mediated disease is selected from the group consisting of systemic mastocytosis, disorder of systemic mast cell activation, tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, injury due to ischemic reperfusion and inflammation. 
     
     
       11. A method according to claim 18 wherein said PGD 2 -mediated disease is nasal occlusion. 
     
     
       12. The compound of  claim 1 , its salt or hydrate thereof, wherein:                    
       A is alkylene which optionally contains oxo group and/or has an unsaturated bond; B is hydrogen, R is COOH or CH 2 OH; X 1  is a single bond; X 2  is a single bond; X 3  is substituted- or unsubstituted-benzothienyl.